Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonist antibodies

摘要

The present disclosure relates to methods for treating or preventing obesity and / or nonalcoholic fatty liver disease (NAFLD) and / or nonalcoholic steatohepatitis (NASH) using a glucagon receptor blocker. In various embodiments, the present disclosure provides for treating or preventing NAFLD / NASH using antagonistic antigen binding proteins, such as fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor. Regarding the method. [Selection] Figure 3